Synergistic Activity of ALK and STAT3 Inhibitors for the Treatment of ALK Mutated Neuroblastoma Cells

被引：0
|
作者：
Hiwatari, M. [1 ]
Watanabe, K. [2 ]
Kimura, S. [2 ]
Takita, J. [2 ]
机构：
[1] Univ Tokyo, Cell Therapy & Transplantat Med, Tokyo, Japan
[2] Univ Tokyo, Pediat, Tokyo, Japan
来源：
PEDIATRIC BLOOD & CANCER | 2018年 / 65卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
PO-354
引用
收藏
页码：S252 / S252
页数：1
相关论文
共 50 条
  • [1] Synergistic Activity of ALK and mTOR Inhibitors for the Treatment of NPM-ALK Positive Lymphoma
    Redaelli, Sara
    Ceccon, Monica
    Pirola, Alessandra
    Peronaci, Marco
    Gambacorti-Passerini, Carlo
    Mologni, Luca
    BLOOD, 2015, 126 (23)
  • [2] Synergistic activity of ALK and mTOR inhibitors for the treatment of NPM-ALK positive lymphoma
    Redaelli, Sara
    Ceccon, Monica
    Antolini, Laura
    Rigolio, Roberta
    Pirola, Alessandra
    Peronaci, Marco
    Gambacorti-Passerini, Carlo
    Mologni, Luca
    ONCOTARGET, 2016, 7 (45) : 72886 - 72897
  • [3] ALK inhibitors increase ALK expression and sensitize neuroblastoma cells to ALK.CAR-T cells
    Bergaggio, Elisa
    Tai, Wei-Tien
    Aroldi, Andrea
    Mecca, Carmen
    Landoni, Elisa
    Nuesch, Manuel
    Mota, Ines
    Metovic, Jasna
    Molinaro, Luca
    Ma, Leyuan
    Alvarado, Diego
    Ambrogio, Chiara
    Voena, Claudia
    Blasco, Rafael B.
    Li, Tongqing
    Klein, Daryl
    Irvine, Darrell J.
    Papotti, Mauro
    Savoldo, Barbara
    Dotti, Gianpietro
    Chiarle, Roberto
    CANCER CELL, 2023, 41 (12) : 2100 - 2116.e10
  • [4] ALK inhibitors increase ALK expression and sensitize neuroblastoma cells to ALK.CAR- T cells
    Bergaggio, Elisa
    Tai, Wei-Tien
    Aroldi, Andrea
    Mecca, Carmen
    Landoni, Elisa
    Nuesch, Manuel
    Mota, Ines
    Metovic, Jasna
    Molinaro, Luca
    Ma, Leyuan
    Alvarado, Diego
    Ambrogio, Chiara
    Voena, Claudia
    Blasco, Rafael B.
    Li, Tongqing
    Klein, Daryl
    Irvine, Darrell J.
    Papotti, Mauro
    Savolodo, Barbara
    Dotti, Gianpietro
    Chiarle, Roberto
    CANCER RESEARCH, 2024, 84 (06)
  • [5] A high-throughput chemical screen identifies synergistic activity between neurotransmitter receptor inhibitors and crizotinib in ALK-mutated neuroblastoma
    Moore, Nathan
    Pukma, Srunphut
    Gray, Nathanael
    George, Rani
    CANCER RESEARCH, 2014, 74 (19)
  • [6] A high-throughput chemical screen identifies synergistic activity between crizotinib and transcriptional CDK inhibitors in ALK-mutated neuroblastoma
    Moore, Nathan F.
    Chipumuro, Edmond
    Hatheway, Clark M.
    Zhang, Tinghu
    Gray, Nathanael S.
    George, Rani E.
    CANCER RESEARCH, 2015, 75
  • [7] Entrectinib and other ALK/TRK inhibitors for the treatment of neuroblastoma
    Pacenta, Holly L.
    Macy, Margaret E.
    DRUG DESIGN DEVELOPMENT AND THERAPY, 2018, 12 : 3549 - 3561
  • [8] ALK Inhibitors for Treatment of Adult-Onset Neuroblastoma
    Stiefel, J.
    Kushner, B.
    Roberts, S.
    Basu, E.
    Modak, S.
    PEDIATRIC BLOOD & CANCER, 2021, 68 : S226 - S226
  • [9] Targeted Therapy for Neuroblastoma: ALK Inhibitors
    Schulte, J. H.
    Schulte, S.
    Heukamp, L. C.
    Astrahantseff, K.
    Stephan, H.
    Fischer, M.
    Schramm, A.
    Eggert, A.
    KLINISCHE PADIATRIE, 2013, 225 (06): : 303 - 308
  • [10] Immunoassays for the quantification of ALK and phosphorylated ALK support the evaluation of on-target ALK inhibitors in neuroblastoma
    Tucker, Elizabeth R.
    Tall, Jennifer R.
    Danielson, Laura S.
    Gowan, Sharon
    Jamin, Yann
    Robinson, Simon P.
    Banerji, Udai
    Chesler, Louis
    MOLECULAR ONCOLOGY, 2017, 11 (08): : 996 - 1006
12345